Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression

Annals of Neurology

Volumn 45, Issue 4, 1999, Pages 504-511

  Jensen, Malene ^a   Schröder, Johannes ^b   Blomberg, Mari ^a   Engvall, Benita ^a   Pantel, Johannes ^b   Ida, Nobuo ^b   Basun, Hans ^a   Wahlund, Lars Olof ^a   Werle, Egon ^b   Jauss, Marek ^b   Beyreuther, Konrad ^b   Lannfelt, Lars ^a   Hartmann, Tobias ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; CEREBROSPINAL FLUID; MIDDLE AGED; PATHOPHYSIOLOGY; TIME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0345291176     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9     Document Type: Article

References (38)

1. Younkin SG. Evidence that Aβ42 is the real culprit in Alzheimer's disease. Ann Neurol 1995;37:287-288
2. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 1996;17:1005-1013
3. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med 1997;3:67-72
4. Tomita T, Maruyama K, Saido TC, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 1997;94:2025-2030
5. Xia W, Zhang J, Kholodenko D, et al. Enhanced production and oligomerization of the 42-residue amyloid β-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem 1997;272:7977-7982
6. Reaume AG, Howland DS, Trusko SP, et al. Enhanced amyloidogenic processing of the β-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Aβ sequence. J Biol Chem 1996;271:23380-23388
7. Johnson-Wood K, Lee M, Motter R, et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 1997;94: 1550-1555
8. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870
9. Müller Hill B, Beyreuther K. Molecular biology of Alzheimer's disease. Annu Rev Biochem 1989;58:287-307
10. Nakamura T, Shoji M, Harigaya Y, et al. Amyloid β protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol 1994;36:903-911
11. Pirttila T, Kim KS, Mehta PD, et al. Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sci 1994;127:90-95
12. Tabaton M, Grazia Nunzi M, Xue R, et al. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 1994;200: 1598-1603
13. van Gool WA, Kuiper MA, Walstra GJM, et al. Concentrations of amyloid β protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;37:277-279
14. Nitsch RM, Rebeck WG, Deng M, et al. Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease: inverse severity of dementia and effect of ApoE genotype. Ann Neurol 1995;37:512-518
15. Lannfelt L, Basun H, Vigo-Pelfrey C, et al. Amyloid β-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. Neurosci Lett 1995;199: 203-206
16. Southwick PC, Yamagata SK, Echols CL, et al. Assessment of amyloid β protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem 1996;66:259-266
17. Tamaoka A, Fukushima T, Sawamura N, et al. Amyloid β protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 1996;151:65-68
18. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648
19. Ida N, Hartmann T, Pantel J, et al. Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996;271:22908-22914
20. Tamaoka A, Sawamura N, Fukushima T, et al. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 1997;148:41-45
21. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ40, and Aβ42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26
22. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945
23. (1-42) as a biochemical marker for Alzheimer's disease: a community-based follow-up study. Neurobiol Aging 1998;19:S161 (Abstract)
24. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-944
25. Folstein MF, Folstein SE, McHugh PR. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
27. Reisberg B, Ferris SH, DeLeon MJ, Crook TJ. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139
28. Raby CA, Morganti-Kossmann MC, Kossmann T, et al. Traumatic brain injury increases β-amyloid peptide I-42 in cerebrospinal fluid. J Neurochem 1998;71:2505-2509
29. Schroder J, Pantel J, Ida N, et al. Cerebral changes and cerebrospinal fluid β-amyloid in Alzheimer's disease: a study with magnetic resonance imaging. Mol Psychiatry 1997;2:505-507
30. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997;17:263-264
31. Gearing M, Mori H, Mirra SS. Aβ-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 1996; 39:395-399
32. Tienari PJ, Ida N, Ikonen E, et al. Intracellular and secreted Alzheimer's beta-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. Proc Natl Acad Sci USA 1997;94:4125-4130
33. Hartmann T, Bieger SC, Bruhl B, et al. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 1997;3:1016-1020
34. Cook DG, Forman MS, Sung JC, et al. Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 1997;3:1021-1023
35. Wild Bode C, Yamazaki T, Capell A, et al. Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J Biol Chem 1997;272:16085-16088
36. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996;46:661-665
37. Van Duijn CM, Clayton DG, Chandra V, et al. Interaction between genetic and environmental risk factors for Alzheimer's disease: a reanalysis of case-control studies. EURODEM Risk Factors Research Group. Genet Epidemiol 1994;11:539-551
38. Tsolaki M, Fountoulakis K, Chantzi E, Kazis A. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of a Greek population. Int Psychogeriatr 1997;9:327-341